Technical Analysis for RGLS - Regulus Therapeutics Inc.

Grade Last Price % Change Price Change
grade F 0.82 -1.57% -0.01
RGLS closed down 1.57 percent on Friday, February 21, 2020, on 28 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: Mar 16
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical RGLS trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
200 DMA Resistance Bearish -1.57%
Outside Day Range Expansion -1.57%
Wide Bands Range Expansion -1.57%
Oversold Stochastic Weakness -1.57%
Wide Bands Range Expansion -1.20%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company utilizes its microRNA product platform to develop anti-miRs, a chemically modified single-stranded oligonucleotides. Its microRNA development candidates target miR-122 in hepatitis C virus infection; miR-21 and miR-221 in hepatocellular carcinoma; miR-21 in kidney fibrosis; miR-33 in atherosclerosis; and miR-10b in glioblastoma. The company has strategic alliances with AstraZeneca AB, GlaxoSmithKline plc, Sanofi, and Alnylam and Isis, as well as a strategic collaboration with Biogen Idec MA Inc. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Biopharmaceutical Diseases Genetics Glioblastoma Regulus Therapeutics Hepatocellular Carcinoma RNA Alnylam Pharmaceuticals Hepatitis C Virus Infection Nucleic Acids Atherosclerosis Microrna

Is RGLS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.74
52 Week Low 0.5
Average Volume 344,398
200-Day Moving Average 0.89
50-Day Moving Average 0.97
20-Day Moving Average 0.97
10-Day Moving Average 0.89
Average True Range 0.09
ADX 24.13
+DI 15.34
-DI 21.98
Chandelier Exit (Long, 3 ATRs ) 1.19
Chandelier Exit (Short, 3 ATRs ) 1.07
Upper Bollinger Band 1.18
Lower Bollinger Band 0.77
Percent B (%b) 0.13
BandWidth 42.82
MACD Line -0.06
MACD Signal Line -0.04
MACD Histogram -0.026
Fundamentals Value
Market Cap 85.1 Million
Num Shares 104 Million
EPS -1.53
Price-to-Earnings (P/E) Ratio -0.54
Price-to-Sales 450.54
Price-to-Book 2.98
PEG Ratio -0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.95
Resistance 3 (R3) 0.96 0.93 0.93
Resistance 2 (R2) 0.93 0.90 0.93 0.92
Resistance 1 (R1) 0.88 0.88 0.90 0.86 0.91
Pivot Point 0.84 0.84 0.86 0.84 0.84
Support 1 (S1) 0.79 0.81 0.82 0.78 0.73
Support 2 (S2) 0.76 0.79 0.75 0.72
Support 3 (S3) 0.70 0.76 0.71
Support 4 (S4) 0.69